The Medical group has plenty of great stocks, but investors should always be looking for companies that are outperforming their peers. Avinger (AVGR) is a stock that can certainly grab the attention of many investors, but do its recent returns compare favorably to the sector as a whole? By taking a look at the stock's year-to-date performance in comparison to its Medical peers, we might be able to answer that question.Avinger is one of 1048 individual stocks in the Medical sector. Collectively, these compan ...

Financial Data and Key Metrics Changes - Total revenue for Q1 2024 was $1.9 million, unchanged from Q4 2023 and Q1 2023 [11] - Gross margin decreased to 18% in Q1 2024 from 20% in Q4 2023 and 34% in Q1 2023, primarily due to lower production activity [11] - Operating expenses increased to $5.4 million in Q1 2024 from $5.0 million in Q4 2023 and $4.9 million in Q1 2023, attributed to increased sales headcount and expenses related to the Zylox-Tonbridge transaction [11] - Net loss for Q1 2024 was $5.5 million, compared to $5.0 million in Q4 2023 and $4.6 million in Q1 2023 [12] - Adjusted EBITDA loss was $3.9 million in Q1 2024, an improvement from a loss of $4.3 million in Q4 2023, remaining the same as Q1 2023 [12] - Cash and cash equivalents totaled $7.2 million as of March 31, 2024 [13] Business Line Data and Key Metrics Changes - The peripheral business continued to progress, with new sales representatives gaining clinical proficiency and building sales pipelines [10] - The Tigereye ST CTO crossing device launched in the second half of the previous year is increasing market penetration [10] Market Data and Key Metrics Changes - Avinger announced a strategic partnership with Zylox-Tonbridge, which will facilitate entry into the greater China market [6][8] - Zylox will invest up to $15 million in Avinger, with the first tranche of $7.5 million already funded [8] Company Strategy and Development Direction - Avinger is focusing on expanding its product offerings in the coronary market, with plans to file an IDE submission for a CTO crossing device by Q3 2024 [9] - The partnership with Zylox-Tonbridge is expected to strengthen Avinger's balance sheet and provide access to new markets, potentially improving gross margins and cost structure [8] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the rapid progress in the partnership with Zylox and the development of the coronary product [14] - The timeline for product registration in China is projected to be completed by the end of 2025, with manufacturing capabilities expected to be validated within the same timeframe [18] Other Important Information - CRG Partners exchanged its Series A preferred stock for new Series A-1 preferred stock, extending principal payments on Avinger's debt to Q1 2027 [13] Q&A Session Summary Question: Anticipated commercialization timeline for products in China - Management expects product registration in China could be achieved by the end of 2025, with manufacturing capabilities coming online within that timeframe [18] Question: Commercialization of products in Europe - Avinger currently markets products under CE Mark in Germany and is prioritizing regulatory clearance efforts for Zylox in China [20] Question: Status of IDE submission for CTO crossing system - The IDE submission requires completion of Phase 3 verification and validation testing, with a target to file by the end of Q3 2024 [22]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Title of each class: Trading Symbol(s): Name of each exchange on which registered: Common Stock, par value $0.001 per share AVGR The Nasdaq Capital Market (Mark One) Commission File Number: 001-36817 ...

Exhibit 99.1 Avinger Reports First Quarter 2024 Results Advances New OCT-Guided Coronary Product Development Redwood City, Calif., May 15, 2024 - Avinger, Inc. (Nasdaq: AVGR), a commercial-stage medical device company developing and marketing the first and only intravascular image-guided, catheter-based systems for diagnosis and treatment of vascular disease, today reported results for the first quarter ended March 31, 2024. First Quarter and Recent Highlights ● Reported first quarter 2024 revenue of $1.9 m ...

Avinger, Inc. (NASDAQ:AVGR) Q4 2023 Earnings Conference Call March 20, 2024 4:30 PM ET Company Participants Matt Kreps - Investor Relations Jeff Soinski - Chief Executive Officer Nabeel Subainati - Principal Financial Officer Conference Call Participants Swayampakula Ramakanth - H.C. Wainwright Operator Greetings. Welcome to Avinger's Fourth Quarter and Full Year 2023 Results Call. At this time, all participants are in listen-only mode. A question-and-answer session will follow the formal presentation. [Ope ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-36817 AVINGER, INC. (Exact name of registrant as specified in its charter) Delaware 20-8873453 (State or other jurisdiction of (I.R.S. Employer incorporation or organ ...

Exhibit 99.1 Avinger Reports Fourth Quarter and Full Year 2023 Results New Strategic Partnership Provides Funding to Support U.S. Growth Initiatives and Coronary Product Development, Opens New Pathway for Sales in Asia Redwood City, Calif., March 20, 2024 - Avinger, Inc. (Nasdaq: AVGR), a commercial-stage medical device company developing and marketing the first and only intravascular image-guided, catheter-based systems for diagnosis and treatment of vascular disease, today reported results for the fourth ...

Avinger, Inc. (NASDAQ:AVGR) Q3 2023 Earnings Conference Call October 26, 2023 4:30 PM ET Company Participants Matt Kreps - Investor Relations Jeff Soinski - Chief Executive Officer Nabeel Subainati - Principal Financial Officer Conference Call Participants Operator Greetings. Welcome to the Avinger Third Quarter 2023 Results Conference Call. At this time, all participants are in a listen-only mode. A question-and-answer session will follow the formal presentation. [Operator Instructions] Please note, this c ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Title of each class: Trading Symbol(s): Name of each exchange on which registered: Common Stock, par value $0.001 per share AVGR The Nasdaq Capital Market FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-36 ...

Avinger, Inc. (NASDAQ:AVGR) Q2 2023 Earnings Conference Call July 27, 2023 4:30 PM ET Company Participants Matt Kreps - Darrow Associates Investor Relations Jeff Soinski - Chief Executive Officer Nabeel Subainati - Principal Financial Officer Conference Call Participants Swayampakula Ramakanth - H.C. Wainwright Operator Greetings and welcome to the Avinger Second Quarter 2023 Results Call. At this time, all participants are in a listen-only mode. A question-and-answer session will follow the formal presenta ...